Chemical Use Among Youth with Incarcerated Parents

| December 29, 2016

article image
Recent analysis indicate at least 1 in 6 Minnesota youth has a parent who is or who has been incarcerated in the past (Shlafer, Reedy, & Atella, 2014). Substance use and abuse in children of incarcerated parents is an issue of health equity. Children of incarcerated parents are often referred to as “hidden victims” (Cunningham & Baker, 2003). This Infographic examines students' self-reported use of alcohol, tobacco, and other drugs, and other indicators of their chemical health

Spotlight

IDEAYA Biosciences

IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA’s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences.

OTHER ARTICLES

The Chemistry of Waterborne Polyurethane Coatings

Article | March 5, 2020

Polyurethanes have long been known to produce coatings that exhibit high toughness, abrasion resistance, enhanced aesthetics, and durability. Solvent-based polyurethanes have traditionally set the performance standard for high durability coatings. However, environmental considerations for low-VOC alternatives and reduced exposure to solvents has stimulated the development of alternative technologies based on waterborne polyurethane systems.

Read More

Transforming Recycled Plastic into Additives for Industrial and Consumer Products

Article | March 24, 2020

With a more increased focus on adding more recycled content to products, it’s becoming very apparent that innovation is required in order to meet these demands. During the Plastics Recycling Conference, Canadian cleantech company GreenMantra Technologies accepted the Association of Plastics Recyclers (APR) Showcase Award, which is given to companies who have a innovative and potentially game-changing idea to advance the recycling of plastics. GreenMantra Technologies is a clean technology company that utilizes a proprietary catalyst and patented depolymerization process to upcycle and transform recycled plastics into value-added synthetic waxes and specialty polymers.

Read More

Removal of non-industrial chemicals from the NICNAS Inventory

Article | March 23, 2020

The Australian Government announced its intention to implement reforms to the way in which industrial chemicals are regulated. The reforms are intended to streamline the process of assessing industrial chemicals to reduce the regulatory burden and to make regulatory effort more proportionate to risk. The Industrial Chemicals Act, which was passed by Parliament in February of 2019 and received Royal Assent in March of 2019, creates a new framework for the regulation of imported or manufactured industrial chemicals. The new scheme, referred to as the Australian Industrial Chemicals Introduction Scheme, or AICIS, will replace the current National Industrial Chemicals Notification and Assessment Scheme, referred to as NICNAS.

Read More

Chemical Recycling of Plastic – Waste No More?

Article | March 2, 2020

When it comes to the circular economy transition, plastics recycling is as much of a challenge as an opportunity. Today, around 25.8 million tons of plastic waste are generated in Europe every year, with less than 30 percent of it getting collected for recycling. This is a huge loss of valuable resources to the economy, and with a huge cost to the environment. Could chemical recycling be part of the ultimate solution, making the plastics value chain more circular whilst providing a profitable new industry branch.

Read More

Spotlight

IDEAYA Biosciences

IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA’s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences.

Events